Bavarian Nordic A/S BV3.F Open Bavarian Nordic A/S in new tab
Bavarian Nordic A/S Analysis (BV3.F)
Is Bavarian Nordic A/S a good investment? Bavarian Nordic A/S (BV3.F) is currently trading at 37.85 EUR.
In terms of valuation, the stock trades at a P/E ratio of 22.40. This valuation is generally in line with the broader market.
Earnings Schedule: Bavarian Nordic A/S is expected to release its next earnings report on Aug. 22, 2024. The market consensus estimate for Forward EPS is 1.13.
Investor FAQ
Does Bavarian Nordic A/S pay a dividend?
No, it does not currently pay a dividend.
What asset class is Bavarian Nordic A/S?
Bavarian Nordic A/S is classified as a Stock.
When is the next earnings date?
The next earnings date is projected to be Aug. 22, 2024. The company currently has a trailing EPS of 1.69.
Company Profile
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2. The company has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
Dividends
Historical Split Corporate Actions
Explore Premium Features
Unlock detailed news and exclusive insights with our Premium subscription.
See Pricing Plans
Community Discussion